generated. In the Berlin Heart VAD (Mediport, Berlin, Germany), the inner surface of the pumps and cannulas are coated with unfractionated heparins. The coating is done by the CARMEDA process (Carmeda, Sa, Lund, Sweden), which has been successfully used for coating cardiopulmonary bypass (CPB) circuits to reduce contact activation of the coagulation system, the need for systemic anticoagulation, and the inflammatory response to the perfusion. [2] [3] [4] A possible disadvantage of coating VADs with unfractionated heparins is an enhanced tendency for the formation of heparin/platelet factor 4 antibodies (HPF4/A), which have been demonstrated to play a pivotal role in the pathogenesis of heparin-induced thrombocytopenia type II (HIT II). 5 HIT II is characterized by the induction of antibodies against complexes of heparin and platelet factor 4. The newly developed antigen-antibody complex binds to platelets and initiates a cascade of events, which result in excessive platelet aggregation that finally leads to severe thromboembolic complications. 6, 7 The goal of the present clinical investigation was as follows:
1. To evaluate whether coating VADs with unfractionated heparin affects the occurrence of HPF4/A 2. To determine whether this is associated with an increased risk for the development of thromboembolic complications, in particular on coated surfaces, in these patients.
Methods
Devices. The Berlin Heart VAD consists of a polyurethane blood pump that is coated with unfractionated heparins (Carmeda). Each pump carries 2 mechanical heart valves and is connected by 2 silicone cannulas. The Berlin Heart system can be used for both single ventricular and biventricular assistance. The LVAD (Baxter Healthcare Corp, Oakland, Calif) is made of polyurethane and connected by Dacron inflow and outflow tracts. It contains biologic heart valves. The TCI HeartMate LVAD chamber (Thermo Cardiosystems) is made of titanium with a rough inner layer, which permits the generation of a natural pseudoendothelium. The DeBakey LVAD (Micromed Technology, the Woodlands, Tex) generates a laminar flow by a rotary blood pump and uses a valveless Dacron outflow graft.
Groups of patients. After approval by the local ethics committee and informed consent, 100 patients who received a VAD in our institution from 1995 to 1999 were enrolled in the investigation. The investigation was performed by using deep-frozen samples, which were collected during hospitalization of the patients. The decision to implant an LVAD or a biventricular assist device system was based on clinical necessity (cardiogenic shock and severe right heart failure). A Berlin Heart system was implanted if the patient needed biventricular assistance. A solely left ventricular Berlin Heart system was planted via a left thoracotomy in patients who had undergone median sternotomy previously. Patients were divided into 2 groups. Group 1 consisted of patients with a heparin-coated VAD (Berlin Heart system), and group 2 consisted of patients with a noncoated VAD (other systems).
Anticoagulation protocol. Before the operation, anticoagulation was switched to unfractionated heparin (UFH; Liquemin) to achieve a target activated partial thromboplastin time value between 40 and 60 seconds. Anticoagulation during implantation with the use of CPB was accomplished with UFH according to the Hepcon HMS (Medtronic HemoTec, Inc, Englewood, Colo; E. M. Parker Company, Inc, Wilmington, Mass). After termination of CPB, the anticoagulant effect of heparin was reversed with protamine sulfate (Hoffmann-La Roche Ltd, Basel, Switzerland). Intravenous heparinization was restarted 6 to 12 hours after the operation to achieve a target activated clotting time of 160 to 180 seconds. Antiplatelet agents were simultaneously administered on the basis of the results of the in vitro platelet aggregation tests. The tests were performed with 20 µmol/L adenosine diphosphate, 100 µL/L epinephrine, 190 µg/mL collagen, and 500 µg/mL arachidonic acid. The target value for adenosine diphosphate-and epinephrine-induced platelet aggregation was 30% to 50% and less than 40% for arachidonic acid-induced aggregation. A decrease of the aggregation to a value of 70% to 90% was regarded as sufficient for collagen-induced platelet aggregation. Antiplatelet therapy was initiated with aspirin, beginning with 50 mg/d up to 200 mg/d as a maximum dose. If patients did not respond to this therapy, dipyridamole (400-1000 mg/d) was given.
After removal of all drainage tubes, patients with the Berlin Heart, Novacor, and DeBakey LVADs were switched to warfarin sodium and aspirin, depending on the results of the platelet function test. Patients on the TCI system were treated with aspirin only. Heparinization was only re-established in cases of an increased risk for thrombus formation (immobilization, parameters of infection as demonstrated by white blood cell count, and measurement of C-reactive protein) and a tendency for hyperaggregation in the platelet aggregation assay, which did not respond to antiplatelet therapy.
Detection of thromboembolism. Thromboembolism was confirmed or excluded by computed tomography, angiography, and Doppler ultrasonography after clinical suspicion. In the Berlin Heart VAD the pumps are placed outside the patient, and because they are transparent, visual examination of the pumps for thrombus formation was performed daily. Thrombus formation was regarded as recurrent if they were found in the pumps on more than 3 occasions during the 3-month period of the investigation.
Detection of HPF4/A. Blood samples were collected before implantation, on the seventh and fourteenth postoperative days, and 3 months later. The samples were tested by the use of the ASSERCHROM HPIA enzyme immunoassay (Diagnostica Stago, Asnierssur-Seine, France). The results were considered positive if an optical density of greater than 0.480 was found at an absorbency level of 492 nm.
Platelet count and heparin-induced platelet aggregation assay. The platelet count was performed daily. The heparin platelet aggregation assay (HIPAA) 8 was performed if the patient had a postoperative platelet count of less than 100,000/mL that failed to recover within 2 days or if a patient had a decrease in the platelet count of greater than 30,000/mL. The HIPAA result was deemed positive when agglutination was observed in 2 of 4 chambers with 0.2 IU/mL heparin and a negative result in the buffer and the 100 IU/mL heparin chambers. In patients who had positive test results for HIT II according to the HIPAA, further anticoagulation was performed with recombinant hirudin (Refludan), with a target activated partial thromboplastin time value of 40 to 60 seconds. 9 Statistical analysis. Statistical analyses of the data were performed with SPSS 7.5 for Windows (SPSS, Inc, Chicago, Ill). Significant differences were confirmed by the Student t test (for continuous data). Qualitative variables were analyzed by the χ 2 test.
Results
There were no significant differences in the biometric data, parameters of infection, and duration of heparinization for the 2 groups. Fifty-five patients belonged to group 1 and 45 to group 2. There were 64 male and 36 female patients, with ages ranging from 18 to 64 years (mean ± SD, 47 ± 10 years). In 63 patients the implantation of the device was necessary because of dilated cardiomyopathy, in 5 because of restrictive cardiomyopathy, in 7 because of acute myocarditis, and in 25 because of ischemic cardiomyopathy. In 51 patients the implantation of a biventricular assist device (Berlin Heart) was necessary. Forty-nine patients received an isolated LVAD (30 Novacor, 7 TCI, 6 Berlin Heart, and 6 DeBakey VAD).
Prevalence and persistence of HPF4/A. In group 1, 32 patients had positive test responses for HPF4/A (21 before the operation), whereas in group 2, 31 patients had positive test results for HPF4/A (25 before the operation, P = .102). No patient had positive results for HPF4/A after discontinuation of heparin treatment. Fourteen patients from group 1 and 18 patients from group 2 had negative results for HPF4/A after discontinuation of heparin. Thirteen patients from group 1 and 14 patients from group 2 continued to have positive results for HPF4/A after discontinuation of heparin. There were no significant differences in the prevalence and persistence of HPF4/A between the 2 groups.
HPF4/A and embolism. Embolic events (cerebral infarction, mesenteric infarction, pulmonary embolism, and peripheral embolization of the extremities) were identified in 10 patients with positive results for HPF4/A in group 1 and 12 with positive results in group 2. There were no thromboembolic events in patients with negative results for HPF4/A. Twenty-two patients in group 1 and 19 in group 2 with negative results for HPF4/A had no occurrence of emboli. There were no significant differences between the 2 groups.
Recurrent pump thromboses and HPF4/A in heparin-coated VADs. In group 1, 11 patients with positive results for HPF4/A and 9 patients with negative results for the antibody exhibited at least 3 repetitive thrombi in the pump. There was no significant difference between the occurrence of repetitive pump thrombus formation for patients with positive and negative HPF4/A results. Twenty-one patients with positive results for HPF4/A had no repetitive thrombus formation in the pump.
Platelet count and HIPAA. The HIPAA was performed in 13 patients: 7 from the coated group and 6 from the noncoated group. Three of these patients had a positive reaction, and in all of these, HPF4/A was detectable in the enzyme-linked immunosorbent assay. One of these 3 patients demonstrated no clinical symptoms of thromboembolism, 1 had a stroke caused by embolization, and the third had acute Leriche syndrome. Three of the 10 patients with a negative HIPAA result had positive results for HPF/4A. There were no significant differences in platelet count and HIPAA for groups 1 and 2.
Discussion
The main findings from our study were that heparin coating of the VAD surface does not enhance HPF4/Aassociated immunologic or thrombogenic reactions. However, the presence of these antibodies is strongly associated with an increased risk of thromboembolism in patients with a VAD. This is of great importance in view of the comparably high prevalence (63%) of antibodies in these patients. HPF4/A plays a pivotal role in HIT II and in the formation of heparin-associated thromboemboli. Large differences have been described in the incidence of these antibodies in patients who undergo different types of operations. Bauer and associates 10 found HPF4/A in 19% of patients before and 51% after cardiac operations, whereas Trossaért, 11 Pouplard, 12 and their colleagues found it in 27% and 25.3% of patients, respectively, after cardiac operations. Visentin and coworkers 13 described an incidence of HPF4/A of 61% after cardiac operations and 4.5% after noncardiac operations; they reported no HPF4/A in patients who did not have operations. Jackson and associates 14 reported an incidence of HPF4/A in 2% of patients who underwent vascular operations. The large fraction of patients who revealed HPF4/A before operations in the present study may be explained by multiple hospitalizations and exposures to heparin before the need for implantation of a VAD.
In our study only patients with positive results for HPF4/A had thromboemboli and clinical symptoms of HIT II. Thus the presence of such antibodies may be regarded as a predictor of an increased risk for the development of thromboembolic complications.
Several findings from this study suggest that coating of the inner surface of VADs with unfractionated heparins does not lead to an immunization against heparins. First, no patient from group 1 (the coated group) had antibodies after reversal of systemic heparinization. Second, there was no difference in the 2 groups in the number of patients whose results became antibody negative after the termination of systemic heparinization or in the incidence of thromboembolic complications. Furthermore, circulating antibodies seemed not to induce thrombus formation on the heparinized surface because there was no difference in the incidence of repetitive pump thrombi between patients with a positive antibody status when compared with patients with a negative status in the heparin-coated group. These clinical data are consistent with the results of recent laboratory investigations, which revealed that HPF4/A does not bind to platelet factor 4 complexed with heparin immobilized by multiple chemical cross linkages. 15 However, further investigations to prove whether this also applies for other Carmeda-coated materials, such as CPB systems or catheters, are required.
In conclusion, we found that patients with a VAD have a high incidence of HPF4/A. These antibodies were strongly associated with an increased risk of development of thromboembolic complications, and the frequency of these complications was independent of whether the inner surface of VAD was coated with heparin. Further investigations are necessary to clarify the precise role played by the HPF4/A in thrombus and embolus formation.
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